Hereditary Gynecologic Cancers

Risk Assessment, Counseling, Testing and Management
      Recognition of women and families at risk for inherited cancer syndromes is critical for both management and prevention of gynecologic cancers as well as other syndrome-associated malignancies. Most hereditary cancer syndromes have risks for multiple cancers, and surveillance for affected women is radically different than for those with sporadic disease. High-penetrance hereditary cancer syndromes account for 5% to 10% of all cancers, including those of the female reproductive organs. In this article, inherited syndromes that involve tumors and malignancies of the uterus and ovaries are discussed.
      • Identification of patients at risk for hereditary cancer syndromes is critical for early diagnosis or prevention of cancers.
      • Many cancer genetic syndromes present with specific clinical or pathological features, or specific family history patterns.
      • Genetic risk assessment and counseling is integral to the process of genetic testing for hereditary cancer syndromes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ziogas A.
        • Gildea M.
        • Cohen P.
        • et al.
        Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer.
        Cancer Epidemiol Biomarkers Prev. 2000; 9: 103-111
      1. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda.
        (Accessed November 10, 2011)
        • Gayther S.A.
        • Russell P.
        • Harrington P.
        • et al.
        The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.
        Am J Hum Genet. 1999; 65: 1021-1029
        • Pal T.
        • Permuth-Wey J.
        • Betts J.A.
        • et al.
        BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
        Cancer. 2005; 104: 2807-2816
        • Rasmus S.J.
        • Gather S.A.
        The contribution of BRCA1 and BRCA2 to ovarian cancer.
        Molec Oncol. 2009; 3: 138-150
        • Brose M.S.
        • Rebbeck T.R.
        • Calzone K.A.
        • et al.
        Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
        J Natl Cancer Inst. 2002; 94: 1365-1372
        • Struewing J.P.
        • Hartge P.
        • Wacholder S.
        • et al.
        The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
        J Natl Cancer Inst Monogr. 1995; 17: 33-35
        • King M.C.
        • Marks J.H.
        • Mandell J.B.
        • New York Breast Cancer Study Group
        Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
        Science. 2003; 302: 643-646
        • Satagopan J.M.
        • Boyd J.
        • Kauff N.D.
        • et al.
        Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2.
        Clin Cancer Res. 2002; 8: 3776-3781
        • Thompson D.
        • Easton D.
        Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.
        Am J Hum Genet. 2001; 68: 410-419
        • Lubinski J.
        • Phelan C.M.
        • Ghadirian P.
        • et al.
        Cancer variation associated with the position of the mutation in the BRCA2 gene.
        Fam Cancer. 2004; 3: 1-10
        • Antoniou A.C.
        • Pharoah P.D.
        • Narod S.
        • et al.
        Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
        J Med Genet. 2005; 42: 602-603
        • Whittemore A.S.
        • Gong G.
        • Imyre J.
        Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results form 3 US population-based case-control studies of ovarian cancer.
        Am J Hum Genet. 1997; 60: 496-504
        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in a case series unselected for family history: a combined analysis of 22 studies.
        Am J Hum Genet. 2003; 72: 117-130
        • Ferla R.
        • Calo V.
        • Cascio S.
        • et al.
        Founder mutations in BRCA1 and BRCA2 genes.
        Ann Oncol. 2007; 18: vi93-vi98
        • Risch H.A.
        • McLaughlin J.R.
        • Cole D.E.
        • et al.
        Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
        Am J Hum Genet. 2001; 68: 700-710
        • Lu K.H.
        • Cramer D.W.
        • Muto M.G.
        • et al.
        A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.
        Obstet Gynecol. 1999; 94: 34-37
        • Suthers G.
        Cancer risks for Australian women with a BRCA1 or BRCA2 mutation.
        Aust N Z J Surg. 2007; 77: 314-319
        • van der Kolk D.M.
        • de Bock G.H.
        • Leegte B.K.
        • et al.
        Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families; high cancer incidence at older age.
        Breast Can Res Treat. 2010; 124: 643-651
        • Evans D.G.R.
        • Young K.
        • Bulman M.
        • et al.
        Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
        Clin Genet. 2008; 73: 338-345
      2. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 22;8:17–29–28.

        • Lakhani S.R.
        • Manek S.
        • Penault-Llorca F.
        • et al.
        Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
        Clin Cancer Res. 2004; 10: 2473-2481
        • Shaw P.A.
        • McLaughlin J.R.
        • Zweemer R.P.
        • et al.
        Histopathologic features of genetically determined ovarian cancer.
        Int J Gynecol Pathol. 2002; 21: 407-411
        • Werness B.A.
        • Ramus S.
        • DiCioccio R.A.
        • et al.
        Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
        Int J Gynecol Pathol. 2004; 23: 29-34
        • Stratton J.F.
        • Gayther S.A.
        • Russell P.
        • et al.
        Contribution of BRCA1 mutations to ovarian cancer.
        N Engl J Med. 1997; 336: 1125-1130
        • Vicus D.
        • Finch A.
        • Cass I.
        • et al.
        Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
        Gynecol Oncol. 2010; 118: 299-302
        • Norquist B.
        • Garcia R.
        • Allison K.
        • et al.
        The molecular pathogenesis of hereditary ovarian carcinoma.
        Cancer. 2010; 116: 5261-5271
        • Callahan M.J.
        • Crum C.P.
        • Mederios F.
        • et al.
        Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
        J Clin Oncol. 2007; 25: 3985-3990
        • Finch A.
        • Shaw P.
        • Rosen B.
        • et al.
        Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
        Gynecol Oncol. 2006; 100: 58-64
        • Hermsen B.B.
        • vanDiest P.J.
        • Berkhof J.
        • et al.
        Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer.
        Int J Cancer. 2006; 119: 1412-1418
        • Narod S.A.
        • Risch H.
        • Moslehi R.
        • et al.
        • Hereditary Ovarian Cancer Clinical Study Group
        Oral contraceptives and the risk of hereditary ovarian cancer.
        N Engl J Med. 1998; 339: 424-428
        • Whittemore A.S.
        • Balise R.R.
        • Pharoah P.D.P.
        • et al.
        Oral contraceptive use and ovarian cancer risk among carries of BRCA1 or BRCA2 mutations.
        Br. J Cancer. 2004; 91: 1911-1915
        • McGuire V.
        • Felberg A.
        • Mills M.
        • et al.
        Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.
        Am J Epidemiol. 2004; 160: 613-618
        • McLaughlin J.R.
        • Risch H.A.
        • Lubinski J.
        • et al.
        • Hereditary Ovarian Cancer Clinical Study Group
        Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
        Lancet Oncol. 2007; 8: 26-34
        • Narod S.A.
        • Dubé M.P.
        • Kiljn J.
        • et al.
        Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
        J Natl Cancer Inst. 2002; 94: 1773-1779
        • Iodice S.
        • Barile M.
        • Rotmensz N.
        • et al.
        Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
        Eur J Cancer. 2010; 46: 2275-2284
        • Gaarenstrom K.N.
        • van der Hiel B.
        • Tollenaar R.
        • et al.
        Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.
        Int J Cancer. 2006; 16: 54-59
        • Oei A.L.
        • Massuger L.F.
        • Bulten J.
        • et al.
        Surveillance of women at high risk for hereditary ovarian cancer is inefficient.
        Br J Cancer. 2006; 94: 814-819
        • Olivier R.I.
        • Lubsen-Brandsma M.A.
        • Berhoef S.
        • et al.
        CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
        Gynecol Oncol. 2006; 100: 20-26
        • Rebbeck T.R.
        • Lynch H.T.
        • Neuhausen S.L.
        • et al.
        Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
        N Engl J Med. 2002; 346: 1616-1622
        • Finch A.
        • Beiner M.
        • Lubinski J.
        • et al.
        • Hereditary Ovarian Cancer Clinical Study Group
        Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation.
        JAMA. 2006; 296: 185-192
        • National Comprehensive Cancer Network Guidelines
        Hereditary Breast and Ovarian Cancer Syndrome. Version 1.2011.
        (Accessed November 25, 2011, with permission)
        • Kauff N.D.
        • Barakat R.R.
        Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
        J Clin Oncol. 2007; 25: 2921-2926
        • Kauff N.D.
        • Satagopan J.M.
        • Robson M.E.
        • et al.
        Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
        N Engl J Med. 2002; 346: 1609-1615
        • Rebbeck T.R.
        • Lynch H.T.
        • Neuhausen S.L.
        • et al.
        Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
        N Engl J Med. 2002; 346: 1616-1622
        • Clark A.S.
        • Domchek S.M.
        Clinical management of hereditary breast cancer syndromes.
        J Mammary Gland Biol Neoplasia. 2011; 16: 17-25
        • ACOG Practice Bulletin
        Hereditary breast and ovarian cancer syndrome.
        Obstet Gynecol. 2009; 113: 957-966
        • Domchek S.M.
        • Friebel T.M.
        • Singer C.F.
        • et al.
        Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
        JAMA. 2010; 304: 967-975
        • Rebbeck T.R.
        • Friebel T.
        • Wagner T.
        • et al.
        Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
        J Clin Oncol. 2005; 23: 7804-7810
        • Eisen A.
        • Lubinski J.
        • Gronwald J.
        • et al.
        Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
        J Natl Cancer Inst. 2008; 100: 1361-1367
        • Armstrong K.
        • Schwartz J.S.
        • Randall T.
        • et al.
        Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
        J Clin Oncol. 2004; 22: 1045-1054
        • Carcangiu M.L.
        • Peissel B.
        • Pasini B.
        • et al.
        Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
        Am J Surg Pathol. 2006; 30: 1222-1230
        • Powell B.C.
        Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
        Gynecol Oncol. 2006; 100: 1-2
        • Powell B.C.
        • Chen L.M.
        • McLennan J.
        • et al.
        Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
        Intl J Gynecol Cancer. 2011; 21: 846-851
        • Rhiem K.
        • Foth D.
        • Wappenschmidt B.
        • et al.
        Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
        Arch Gynecol Obstet. 2011; 283: 623-627
        • Hirst J.E.
        • Gard G.B.
        • McIllroy K.
        • et al.
        High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.
        Intl J Gynecol Cancer. 2009; 19: 826-829
        • Rabban J.T.
        • Crawford B.
        • Chen L.M.
        • et al.
        Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women with BRCA mutations.
        Am J Surg Pathol. 2009; 33: 111-119
        • Medeiros F.
        • Muto M.G.
        • Lee Y.
        • et al.
        The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.
        Am J Surg Pathol. 2006; 30: 3230-3236
        • Narod S.A.
        • Sun P.
        • Ghadirian P.
        • et al.
        Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
        Lancet. 2001; 357: 1467-1470
        • Powell B.C.
        • Kenley E.
        • Chen L.M.
        • et al.
        Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
        J Clin Oncol. 2005; 23: 127-132
        • Chapman J.S.
        • Powell C.B.
        • McLennan J.
        • et al.
        Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
        Gynecol Oncol. 2011; 122: 339-343
        • Lavie O.
        • Ben-Arie A.
        • Segev Y.
        • et al.
        BRCA germline mutations in women with uterine serous carcinoma–still a debate.
        Int J Gynecol Cancer. 2010; 20: 1531-1534
        • Bruchim I.
        • Amichay K.
        • Kidron D.
        • et al.
        BRCA 1/2 germline mutations in Jewish patients with uterine serous carcinoma.
        Int J Gynecol Cancer. 2010; 20: 1148-1153
        • Lacour R.A.
        • Westin S.N.
        • Meyer L.A.
        • et al.
        Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
        Gynecol Oncol. 2011; 121: 358-363
        • Chetrit A.
        • Hirsh-Yechezkel G.
        • Ben-David Y.
        • et al.
        Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
        J Clin Oncol. 2008; 26: 20-25
        • Ramus S.J.
        • Fishman A.
        • Pharoah P.D.P.
        • et al.
        Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
        EJSO. 2001; 27: 278-328
        • Boyd J.
        • Sonoda Y.
        • Federici M.G.
        • et al.
        Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
        JAMA. 2000; 283: 2260-2265
        • Foulkes W.D.
        BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.
        Fam Cancer. 2006; 5: 135-142
        • McCabe N.
        • Lord C.J.
        • Tutt A.N.
        • et al.
        BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
        Cancer Biol Ther. 2005; 4: 934-936
        • Farmer H.
        • McCabe N.
        • Lord C.J.
        • et al.
        Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
        Nature. 2005; 434: 917-921
        • Kennedy R.D.
        • Quinn J.E.
        • Mullan P.B.
        • et al.
        The role of BRCA1 in the cellular response to chemotherapy.
        J Natl Cancer Inst. 2004; 96: 1659-1668
        • Weitzel J.N.
        • Lagos V.I.
        • Herzog J.S.
        • et al.
        Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families.
        Cancer Epidemiol Biomarkers Prev. 2007; 16: 1615-1620
        • Palma M.D.
        • Domchek S.M.
        • Stopfer J.
        • et al.
        The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
        Cancer Res. 2008; 68: 7006-7014
        • Myriad Genetic Laboratories
        (Accessed November 28, 2011)
        • Stadler Z.K.
        • Saloustros E.
        • Hansen N.A.
        • et al.
        Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
        Br Cancer Res Treat. 2010; 123: 581-585
        • Hampel H.
        • Frankel W.
        • Panescu J.
        • et al.
        Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
        Cancer Res. 2006; 66: 7810-7817
        • Wijnen J.
        • deLeeuw W.
        • Vasen H.
        • et al.
        Familial endometrial cancer in female carriers of MSH6 germline mutations.
        Nat Genet. 1999; 23: 142-144
        • de la Chapelle A.
        The incidence of Lynch syndrome.
        Fam Cancer. 2005; 4: 233-237
        • Hampel H.
        • Frankel W.L.
        • Martin E.
        • et al.
        Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
        J Clin Oncol. 2008; 26: 5783-5788
        • Malander S.
        • Rambech E.
        • Kristoffersson U.
        • et al.
        The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
        Gynecol Oncol. 2006; 101: 238-243
        • Rubin S.C.
        • Blackwood M.A.
        • Bandera C.
        • et al.
        BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
        Am J Obstet Gynecol. 2006; 178: 670-677
        • Lu K.H.
        • Schorge J.O.
        • Rodabaugh K.J.
        • et al.
        Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer.
        J Clin Oncol. 2007; 25: 5158-5164
        • Walsh M.D.
        • Cummings M.C.
        • Buchanan D.D.
        • et al.
        Molecular pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients.
        Clin Cancer Res. 2008; 14: 1692-1700
        • Lu K.H.
        Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis.
        Fam Cancer. 2008; 7: 53-58
        • Matthews K.S.
        • Estes J.M.
        • Conner M.G.
        • et al.
        Lynch syndrome in women less than 50 years of age with endometrial cancer.
        Obstet Gynecol. 2008; 111: 1161-1166
        • Aarnio M.
        • Sankila T.
        • Pukkala E.
        • et al.
        Cancer risk in mutation carriers of DNA mismatch repair genes.
        Intl J Cancer. 1999; 81: 214-218
        • Bonadona V.
        • Bonaiti B.
        • Olschwang S.
        • et al.
        Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
        JAMA. 2011; 305: 2304-2310
        • Quehenberger F.
        • Vasen H.F.
        • van Houwelingen H.C.
        Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment.
        J Med Genet. 2005; 42: 491-496
        • Baglietto L.
        • Lindor N.M.
        • Dowty J.G.
        • et al.
        • Dutch Lynch Syndrome Study Group
        Risks of Lynch syndrome cancers for MSH6 mutation carriers.
        J Natl Cancer Inst. 2010; 102: 193-201
        • Senter L.
        • Clendenning M.
        • Sotamaa K.
        • et al.
        The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations.
        Gastroenterology. 2008; 135: 419-428
        • Vasen H.F.
        • Stormorken A.
        • Menko F.H.
        • et al.
        MSH2 mutation carriers are at higher risk for cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
        J Clin Oncol. 2001; 19: 4074-4080
        • Hampel H.
        • Stephens J.A.
        • Pukkala E.
        • et al.
        Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.
        Gastroenterology. 2005; 129: 415-421
        • Watson P.
        • Butzow R.
        • Lynch H.T.
        • et al.
        The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.
        Gynecol Oncol. 2001; 82: 223-228
        • Barrow E.
        • Robinson L.
        • Alduaij W.
        • et al.
        Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations.
        Clin Genet. 2009; 75: 141-149
        • Stoffel E.
        • Mukherjee B.
        • Raymond V.M.
        • et al.
        Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.
        Gastroenterology. 2009; 137: 1621-1627
        • Garg K.
        • Soslow R.A.
        Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma.
        J Clin Pathol. 2009; 62: 679-684
        • Umar A.
        • Boland D.R.
        • Terdiman J.P.
        • et al.
        Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
        J Natl Cancer Inst. 2004; 96: 261-268
        • Ketabi Z.
        • Bartuma K.
        • Bernstein I.
        • et al.
        Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.
        Gynecol Oncol. 2011; 121: 462-465
        • Hampel H.
        • Stephens J.A.
        • Pukkala E.
        • et al.
        Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.
        Gastroenterology. 2005; 129: 415-421
        • Resnick K.
        • Straughn Jr, J.M.
        • Backes F.
        • et al.
        Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients.
        Obstet Gynecol. 2009; 114: 530-536
        • Hendriks Y.M.
        • Wagner A.
        • Morreau H.
        • et al.
        Cancer risk in hereditary non-polyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.
        Gastroenterology. 2004; 127: 17-25
        • Dunlop M.G.
        • Farrington S.M.
        • Carothers A.D.
        • et al.
        Cancer risk associated with germline DNA mismatch repair gene mutations.
        Hum Mol Genet. 1997; 6: 105-110
        • Soliman P.T.
        • Broaddus R.R.
        • Schmeler K.M.
        • et al.
        Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?.
        J Clin Oncol. 2005; 23: 9344-9350
        • Broaddus R.R.
        • Lynch H.T.
        • Chen L.
        • et al.
        Pathologic features of endometrial carcinoma associated with HNPCC.
        Cancer. 2006; 106: 87-94
        • Westin S.N.
        • Lacour R.A.
        • Urbauer D.L.
        • et al.
        Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome.
        J Clin Oncol. 2008; 26: 5965-5971
        • Garg K.
        • Leitao M.
        • Kauff N.
        • et al.
        Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
        Am J Surg Pathol. 2009; 33: 925-933
        • DeLair D.
        • Oliva E.
        • Köbel M.
        • et al.
        Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases.
        Am J Surg Pathol. 2011; 35: 36-44
        • Lu K.H.
        Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis.
        Fam Cancer. 2008; 7: 53-58
        • Renkonen-Sinisalo L.
        • Butzow R.
        • Leminen A.
        • et al.
        Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome.
        Int J Cancer. 2006; 120: 821-824
        • Auranen A.
        • Joutsiniemi T.
        A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families.
        Acta Obstet Gynecol Scand. 2011; 90 (437–4)
        • Gerritzen L.H.
        • Hoogerbrugge N.
        • Oei A.L.
        • et al.
        Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome.
        Fam Cancer. 2009; 8: 391-397
        • Lynch H.T.
        • Casey M.J.
        Prophylactic surgery prevents endometrial and ovarian cancer in Lynch syndrome.
        Nat Clin Pract Oncol. 2007; 4: 672-673
        • Chen L.M.
        • Yang K.Y.
        • Little S.E.
        • et al.
        Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families.
        Obstet Gynecol. 2007; 110: 18-25
        • Kwon J.S.
        • Sun C.C.
        • Peterson S.K.
        • et al.
        Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome.
        Cancer. 2008; 113: 326-335
        • Palma L.
        • Marcus V.
        • Gilbert L.
        • et al.
        Synchronous occult cancers of the endometrium and fallopian tube in an MSH2 mutation carrier at time of prophylactic surgery.
        Gynecol Oncol. 2008; 111: 575-578
        • Giardiello F.M.
        • Brensinger J.D.
        • Tersmette A.C.
        • et al.
        Very high risk of cancer in familial Peutz-Jeghers syndrome.
        Gastroenterology. 2000; 119: 447-453
        • Chen K.T.
        Female genital tract tumors in Peutz-Jeghers syndrome.
        Hum Pathol. 1986; 17: 858-861
        • Fujiwaki R.
        • Takahashi K.
        • Kitao M.
        Adenoma malignum of the uterine cervix associated with Peutz-Jeghers syndrome.
        Int J Gynaecol Obstet. 1996; 53: 171-172
        • Pilarski R.
        Cowden syndrome: a critical review of the literature.
        J Genet Counsel. 2009; 18: 13-27
        • Rustad C.F.
        • Bjørnslett M.
        • Heimdal K.R.
        • et al.
        Germline PTEN mutations are rare and highly penetrant.
        Hered Can Clin Pract. 2006; 4: 177-185
      3. Genetic counseling is endorsed by the following. American College of Medical Genetics, American College of Obstetrics and Gynecology, American Gastroenterology Association, American Society of Clinical Oncology, American Society of Breast Surgeons, American Society of Colon and Rectal Surgeons, International Society of Nurses in Genetics, National Comprehensive Cancer Network, National Society of Genetic Counselors, Oncology Nursing Society, Society of Gynecologic Oncology, Society of Surgical Oncology and US Preventative Services Task Force.

        • Parmigiani G.
        • Chen S.
        • Iversen Jr, E.S.
        • et al.
        Validity of models for predicting BRCA1 and BRCA2 mutations.
        Ann Intern Med. 2007; 147: 441-450
        • Weitzel J.N.
        • Lagos V.I.
        • Cullinane C.A.
        • et al.
        Limited family structure and BRCA gene mutation status in single cases of breast cancer.
        JAMA. 2007; 297: 2587-2595